Preclinical Data Showing Strong Immunogenicity And Protection With IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online On bioRxiv
Portfolio Pulse from Happy Mohamed
IMUNON, Inc. (NASDAQ:IMNN) has announced the availability of a manuscript on bioRxiv detailing the strong immunogenicity and protection offered by its PlaCCine DNA-based vaccines. The study used IMUNON's proprietary formulation against the spike proteins from two SARS-CoV-2 variants. The data shows that the vaccine is stable for up to one year at 4°C, induces spike-specific neutralizing antibodies and cytotoxic T cells, and can suppress viral replication. The company plans to commence a human clinical trial with PlaCCine in SARS-CoV-2 during the first quarter of 2024.
August 07, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IMUNON's PlaCCine DNA-based vaccine shows promising preclinical results, with human trials planned for Q1 2024. This could potentially boost the company's stock in the short term as investors may see this as a positive development.
The news of promising preclinical results for IMUNON's PlaCCine DNA-based vaccine is directly related to the company's core business. The announcement of upcoming human trials indicates progress in the company's vaccine development, which could potentially boost investor confidence and positively impact the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100